Why DeepDerm
Clinician-first. Evidence-driven. Built for better skin outcomes.
Each year, over 1.4 million skin biopsies are performed in Australia alone — and up to 40% are later found benign, costing the healthcare system over $400 million annually.
DeepDerm aims to reduce unnecessary biopsies and enable earlier, more accurate detection of melanoma — saving time, cost, and lives.
AI Intelligence
Real-time multimodal analysis at point-of-care.
Clinical Insight
Designed with dermatologists, validated in trials.
Equity in Access
Bringing early detection to every community.
Designed for Clinical Simplicity
DeepDerm integrates seamlessly into existing clinical workflows — from teledermatology to full-body mole mapping.
It’s portable, non-invasive, and interpretable — so you can focus on patients, not pixels.
Our Impact
94% Accuracy
Validated in pilot trials
>1000 Images Analysed
Across real clinical settings
2 Clinical Partners
MoleMap & PeterMac
Our Vision
Building the next generation of AI-assisted skin care
Skin cancer remains Australia’s most diagnosed cancer — but DeepDerm is changing that. By combining advanced thermal and spectral imaging with AI, we empower clinicians to detect abnormalities invisible to the naked eye.
Featured Partners
